Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon And Barr Reach Patent Settlements For Provigil, Actiq

This article was originally published in The Pink Sheet Daily

Executive Summary

Barr could gain up to two months of exclusivity for its Actiq generic.

You may also be interested in...



Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile

Cephalon plans to submit information to FDA within “the next few weeks.”

Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile

Cephalon plans to submit information to FDA within “the next few weeks.”

See You In September: Cephalon Anticipates Generic Actiq Ahead Of Fentora Follow-On

Barr reports plans to begin selling a generic version of the pain drug in the second half of September.

Related Content

Topics

UsernamePublicRestriction

Register

PS063719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel